Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16Docetaxel 15trastuzumab deruxtecan 14Radiotherapy 13Drug Therapy 13Standard of Care 12Letrozole 12Fulvestrant 12dalpiciclib 11pembrolizumab 9exemestane 9Epirubicin 9Anastrozole 9sacituzumab govitecan 8palbociclib 8eribulin 8Specimen Handling 8Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Neoadjuvant Therapy 6Magnetic Resonance Spectroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Biosimilar Pharmaceuticals × Breast × Clear all
NCT07246317 2025-11-28

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
188 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡